Vaccine description | |
---|---|
Target | SARS-CoV-2 |
Vaccine type | Inactivated |
Clinical data | |
Other names | ERUCOV-VAC |
Routes of administration | Intramuscular |
Legal status | |
Legal status |
Part of a series on the |
COVID-19 pandemic |
---|
|
COVID-19 portal |
Turkovac[1] (pronunciation: ['tɜ:rkəvæk]) is a COVID-19 vaccine developed by Turkish Ministry of Health and Erciyes University.
In November 2020, TURKOVAC started on phase I trials with 44 participants in Turkey.[2]
In February 2021, TURKOVAC started on phase II trials with 250 participants in Turkey.[3]
In June 2021, TURKOVAC started on phase III trials with 40,800 participants in Turkey.[4] As of 2023[update] phase III trials continue.[5]
On 25 November 2021, the Turkish Minister of Health reported that Turkovac's application for emergency use authorization had been filed.[6] On 22 December, Turkish President Recep Tayyip Erdogan announced the emergency use approval of Turkovac.[7]
Development | |||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|
Classes | |||||||||||
Administration | |||||||||||
Vaccines |
| ||||||||||
Inventors/ researchers | |||||||||||
Controversy | |||||||||||
Related | |||||||||||
|